|
Synonyms: etaratuzumab | hLM60 | MEDI-522
Compound class:
Antibody
Comment: Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Bioactivity Comments |
| The affinity of the originating monoclonal, Vitaxin® (MEDI-523) was optimised by mutation of the Fc region (specifically isoleucine 332 of the CH2 domain) to generate etaracizumab (MEDI-522) [4], which expresses I332E mutation (Vitaxin-1M in the referenced patent). In the binding assays performed as part of the patent application Vitaxin® had a measured Kd of 3470nM. |
| Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
